I27. BSRBR: IMPACT
Kimme Hyrich1
1Arthritis Research Centre for Epidemiology, University of Manchester, Manchester, UK

The BSRBR-RA recruited its first patient in 2001. In 2014, the study is now following over 20,000 patients across the UK and continues to recruit patients starting biologic therapies. Originally designed as a simple research study to address questions about biologic safety, the study has evolved into an important information tool, with emerging data valuable to rheumatology, the wider medical community, the pharmaceutical industry, international drug regulators and most importantly, for patients considering or receiving biologic therapies, ensuring biologic drugs are being used in the safest and most effective way possible. This talk will summarize these impacts, highlighting the role of the BSRBR-RA over the past 13 years.

Disclosure statement: The author has declared no conflicts of interest.